0.4654
전일 마감가:
$0.4905
열려 있는:
$0.48
하루 거래량:
159.41K
Relative Volume:
0.42
시가총액:
$50.75M
수익:
$5.12M
순이익/손실:
$-67.00M
주가수익비율:
-0.3166
EPS:
-1.47
순현금흐름:
$-38.94M
1주 성능:
-15.83%
1개월 성능:
-16.59%
6개월 성능:
-70.36%
1년 성능:
-93.33%
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
명칭
Verrica Pharmaceuticals Inc
전화
484-453-3300
주소
10 NORTH HIGH STREET, WEST CHESTER, PA
VRCA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
VRCA
Verrica Pharmaceuticals Inc
|
0.4654 | 50.75M | 5.12M | -67.00M | -38.94M | -1.47 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-11-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2024-11-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2023-07-25 | 업그레이드 | Needham | Hold → Buy |
2023-03-22 | 개시 | Jefferies | Buy |
2023-02-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2022-05-25 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2021-05-14 | 개시 | RBC Capital Mkts | Outperform |
2020-12-24 | 재확인 | H.C. Wainwright | Buy |
2020-07-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
2020-06-30 | 재확인 | H.C. Wainwright | Buy |
2020-06-24 | 개시 | Northland Capital | Outperform |
2020-03-24 | 개시 | Needham | Buy |
2019-02-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Verrica Pharmaceuticals Inc 주식(VRCA)의 최신 뉴스
GLP-1 Receptor Agonist Market Is Booming Worldwide 2025-2032: Verrica Pharmaceuticals, AbbVie Inc. - newstrail.com
Leadership Changes at Madrigal Pharmaceuticals Mark New Phase of Growth - MyChesCo
Verrica Pharmaceuticals Appoints Dr. Noah Rosenberg as Chief Medical Officer - MSN
Verrica Pharmaceuticals (NASDAQ:VRCA) Earns "Neutral" Rating from HC Wainwright - MarketBeat
New Drug Application Submitted in Japan for Verrica Pharmaceuticals’ TO-208 - MSN
Needham & Company LLC Reiterates “Hold” Rating for Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World
HC Wainwright Analysts Decrease Earnings Estimates for VRCA - Defense World
What is HC Wainwright’s Forecast for VRCA FY2028 Earnings? - Defense World
Verrica Pharmaceuticals (NASDAQ:VRCA) Receives “Neutral” Rating from HC Wainwright - Defense World
Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH - MSN
H.C. Wainwright maintains Neutral on Verrica stock after Q1 update By Investing.com - Investing.com Canada
Verrica Pharmaceuticals at Needham Conference: Strategic Restructuring and Growth By Investing.com - Investing.com Canada
In face of U.S. stock market selloff, shares of West Chester firm are on the rise - The Business Journals
Verrica Pharmaceuticals Reports Strong Demand-Led Growth In Ycanth® In Q1 2025 - marketscreener.com
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025 - The Manila Times
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in - GlobeNewswire
Record-Breaking Quarter: YCANTH Crosses 10K Units Milestone with 17% Growth - Stock Titan
Verrica Pharmaceuticals Adds Dr. Gavin Corcoran to Board of Directors - MSN
Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now - MSN
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors - The Manila Times
Verrica Pharmaceuticals appoints new board member - Investing.com Australia
Verrica Pharmaceuticals appoints new board member By Investing.com - Investing.com Canada
Palvella Therapeutics Announces Late-Breaking Presentation at Global Pediatric Dermatology Congress - MyChesCo
Verrica Pharmaceuticals expands board with new director By Investing.com - Investing.com Canada
Verrica Pharmaceuticals Appoints Dr. Corcoran as Director - TipRanks
Verrica Pharmaceuticals expands board with new director - Investing.com
Strategic Move: Verrica Adds Formation Bio CDO to Board Amid YCANTH Success - Stock Titan
Verrica Pharmaceuticals to Present at Needham Healthcare Conference - MSN
Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo
Harmony, Lungpacer, Verrica and Arbutus make C-suite hires - The Business Journals
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Exclusive: Verrica Pharmaceuticals CEO Fireside Chat at Major Healthcare Conference - Stock Titan
Verrica Pharmaceuticals appoints new CMO to advance skin treatments By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer - GlobeNewswire
Verrica Pharmaceuticals appoints Rosenberg as CMO - MSN
Verrica Pharmaceuticals appoints new CMO to advance skin treatments - Investing.com
Dermatology Drug Pioneer Joins Verrica to Accelerate YCANTH Growth - Stock Titan
VRCA stock plunges to 52-week low, touches $0.5 - Investing.com
Verrica Pharmaceuticals Inc (VRCA)’s stock price range in the last year - US Post News
Verrica Pharmaceuticals Reports Positive Q4 2024 Results - TipRanks
Verrica Pharmaceuticals’ chief legal officer sells shares for $2,804 By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Inc (VRCA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):